Chapter from the book *When Things Go Wrong - Diseases and Disorders of the Human Brain*
Downloaded from: [http://www.intechopen.com/books/when-things-go-wrong-diseases-and-disorders-of-the-human-brain](http://www.intechopen.com/books/when-things-go-wrong-diseases-and-disorders-of-the-human-brain)

Interested in publishing with IntechOpen?
Contact us at [book.department@intechopen.com](mailto:book.department@intechopen.com)
How Much Serotonin in the CNS is Too Much?

Rui Tao and Zhiyuan Ma
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida USA

1. Introduction

Serotonin syndrome is a neurological disorder primarily associated with inappropriate uses of serotonin (5HT)-promoting drugs such as serotonin reuptake inhibitors (SRIs), monoamine oxidase inhibitors (MAOIs) or 3,4-Methylenedioxyamphetamine (MDMA; Ecstasy) (Boyer et al., 2005; Karunatilake et al., 2006; Parrott, 2002; Paruchuri et al., 2006). The primary cause of the syndrome is due to a global increase in brain 5HT that can potentially activate all 14 subtypes of 5HT receptors (5HTRs). However, the significance of a given subtype contributing to the syndrome is not always the same, depending on the amount of 5HT evoked by drugs, physical condition of individual patients and even surrounding environment of drug administration. As a result, signs and symptoms of the syndrome vary widely (Mills, 1995) and thus it has been a clinical challenge to get an accurate diagnosis. Regardless, it has been recognized since the early 1990’s that the symptoms of the syndrome can be generally classified into 3 categories: mental state changes (mood swings), neuromuscular hyperactivity and autonomic dysfunction (Sternbach, 1991). Among these, neuromuscular and autonomic symptoms can be replicated in laboratory animals with MAOIs combined with 5HT precursors (Shioda et al., 2004) or by MDMA at a high dose (Baumann et al., 2008a; Spanos et al., 1989). Thus, despite many difficulties in clinical research, there are some great advances in understanding serotonin syndrome thanks primarily to preclinical investigation in animals.

Increasingly, the term “serotonin toxicity” has been used interchangeably with “serotonin syndrome”, particularly in MDMA-related research. This is mainly because MDMA at high doses could cause a reduction in 5HT content in the brain and possibly axonal degeneration (Bhide et al., 2009; Malberg et al., 1998). In fact, there is no evidence indicating that clinically relevant doses of MDMA could produce such effects or neural death although symptoms of the serotonin syndrome occur [details reviewed by (Baumann et al., 2007)]. For these reasons, we avoided using the term “toxicity” in this study unless more relevant information such as levels of cell death is available in clinically relevant literature.

To address the neurological mechanisms underlying the cause of the serotonin syndrome, we will review recent research findings on how brain 5HT is dynamically altered following administration of 5HT-promoting drugs by which the syndrome would potentially be evoked. We will focus on preclinical data since most experimental studies have been carried out in rodents (rats and mice). If available, human data will also be included for comparison. Additionally, the role of 5HT receptors in the syndrome will be discussed.
2. Dynamic changes in 5HT concentration

Despite the fact that brain 5HT can be found in both the extracellular space and intracellular compartments, extracellular 5HT ($5HT_{ext}$) is the one involved in neurotransmission in the brain. Therefore, first of all, we will review literature on $5HT_{ext}$ concentration which, in normal physiological condition, likely reflects the functional activity of serotonergic neurons. While an exhaustive literature review is not possible here, representative findings will be mentioned. For comparison, data related to the level of intracellular 5HT (non-functional component) will also be included. Pharmacologically, 5HT-promoting drugs could elevate $5HT_{ext}$ to a particular level resulting in improvement of behavioral response and enhancement of mood without causing mental impairment. Thus in the second part we will review literature concerning the $5HT_{ext}$ level at which behavioral incompetence can be improved in response to 5HT-promoting drugs. Thirdly, we will seek evidence of the upper limit level (threshold) above which $5HT_{ext}$ is too high in the brain and potentially causes serotonin syndrome.

2.1 Normal extracellular concentration

As a neurotransmitter, 5-hydroxytryptamine (5HT; serotonin) is synthesized mainly at serotonergic axon terminals through decarboxylation of 5-hydroxytryptophan (5HTP). Newly synthesized 5HT molecules have three possible fates as follows:

1. uptaken into vesicles by the vesicular monoamine transporter-2 (VMAT2);
2. oxidized by mitochondrial monoamine oxidase-A ($MAO_A$) followed by aldehyde dehydrogenase into 5-hydroxyindoleacetic acid (5HIAA);
3. spontaneously released into the extracellular space through reverse transporters (Gobbi et al., 1993).

However, newly synthesized 5HT molecules are not randomly or equally directed into these three pathways. Their direction depends on physical states and drug action properties in medication. Normally, almost all newly synthesized 5HT molecules are uptaken into vesicles against concentration gradients. Although little is known about mammalian vesicular 5HT concentrations, it is suggested that there may be 270 mM (or $1.6 \times 10^{23}$ molecules) in a 5HT vesicle of leech Retzius neurons (Bruns et al., 1995; Bruns et al., 2000). Generally in the brain, over 99% of 5HT molecules are stored in the synaptic vesicles. The amount of intracellular 5HT can be estimated using homogenized brain tissue. However, it should be kept in mind that the measures likely mirror intensity of serotonergic innervations (Schaefer et al., 2008), but not functional activity of neurotransmission. Nevertheless, the range of 5HT content in the homogenized brain is 1 to 2 nmol/g (Baumann et al., 2008a; Bhide et al., 2009; Grahame-Smith et al., 1974; Malberg et al., 1998). Moreover, raphe nuclei have relatively higher contents than other regions (Adell et al., 1991b). A similar range is also found in the mouse brain (Kim et al., 2005; Pothakos et al., 2010).

Several studies have been carried out to measure 5HT content in the post-mortem human brain (Parsons et al., 1992; Seidl et al., 1999). In general, 5HT is in the range of 100-400 pmol/g in homogenized tissues. Since 5HT is rapidly oxidized in the post-mortem tissues, it is likely that the level in the human brain is underestimated.
5HT\textsubscript{ext} is considered to be critical in maintaining mood and other affective functioning, although normally its quantity is estimated to be less than 0.1% of total 5HT molecules in the brain. At such an exceptionally small quantity, it is a challenge to determine its level in the human brain. Indeed, a PubMed search indicates that there are no relevant data available in clinical literature. Despite this, highly sensitive approaches have been developed during the last two decades for laboratory animals. For instance, Adell et al. measured 5HT\textsubscript{ext} in the cerebrospinal fluid using conventional microdialysis in the frontal cortex, striatum, hypothalamus, hippocampus, inferior colliculus and raphe nuclei, demonstrating that the 5HT\textsubscript{ext} concentration is in the range of 0.5-2 nM (Adell et al., 1991b). Thus, it appears that 5HT\textsubscript{ext} in the rat cerebrospinal fluid is at a low nanomolar level. The same conclusion has been obtained by other studies with rats and mice using zero-net-flux microdialysis (Calcagno et al., 2007; Gardier et al., 2003; Mathews et al., 2004; Tao et al., 2000).

The amount and distribution of 5HT into the extracellular space are strongly implicated in many mental health problems. Physiologically, the concentration of 5HT\textsubscript{ext} is constantly kept at a state of equilibrium, involving balanced regulation between spontaneous release, 5HT\textsubscript{1A}R feedback inhibition and reuptake mechanisms as demonstrated in in vitro and in vivo studies (Becquet et al., 1990; Blier, 2001; Sharp et al., 2007; Wolf et al., 1986). On the other hand, the intracellular concentration in vesicles of serotonergic terminals is at a high milimolar (mM) level, implying that intracellular 5HT can rapidly elevate 5HT\textsubscript{ext} to an extraordinary level in response to 5HT-promoting drugs. The response scale can be widely variable, ranging from a several-fold to a hundred-fold increase (Rutter et al., 1995; Shioda et al., 2004; Zhang et al., 2009). Neuropharmacological investigations into the level of increased 5HT\textsubscript{ext} in response to 5HT-promoting drugs will be highlighted in the next section.

2.2 Therapeutic elevation of 5HT\textsubscript{ext} by 5HT-promoting drugs

Many psychoactive drugs used for patients are able to elevate 5HT\textsubscript{ext} in the brain. To better elucidate the neuropharmacological range of extracellular concentrations, we focus on three categories of 5HT-promoting drugs: serotonin reuptake inhibitors (SRIs), monoamine oxidase inhibitors (MAOIs) and 5-hydroxyl-L-tryptophan (5HTP). SRIs, which elevate 5HT\textsubscript{ext} by blocking 5HT from reentering synapses, have been widely prescribed for decades in the treatment for depression, anxiety and posttraumatic stress disorders. MAOIs are one of the oldest classes of antidepressants, functioning by increasing extravesicular accumulation and spontaneous release. 5HTP is the immediate precursor compound for 5HT synthesis, which is considered to be an important supplemental ingredient in promoting mood (Parker et al., 2011). Altogether, 5HT\textsubscript{ext} elevation is a part of critical mechanisms in the course of medical treatment for some mental diseases although other mechanisms based on 5HT receptors and relevant intracellular signaling pathways are also involved (Sharp et al., 2011). Up to date, laboratory methods for determining 5HT release in patients’ brain are not available and thus how much elevation of 5HT\textsubscript{ext} is sufficient to improve mental health in humans is unknown. The relevant knowledge on the neurochemical effects of these drugs is almost exclusively obtained by animal studies.

There are several members in the SRI family, mainly (but not exhaustively) comprising selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs). For the last three decades a variety of approaches and treatment protocols have been examined on animals to investigate how
these drugs act against 5HT reuptake into serotonergic neurons in the brain. It appears that acute systemic injection could cause only a regionally selective increase in 5HT_{ext} (Beyer et al., 2008; David et al., 2003; Rutter et al., 1993). At clinically relevant doses, the maximum elevation evoked by SRI is relatively low, at less than a 2-fold increase over baseline. This is because a global increase in 5HT_{ext} by systemic injection would activate autoreceptors, namely 5HT_{1A}Rs in the raphe that inhibit discharge-dependent release of 5HT at axon terminals, limiting further increase in 5HT_{ext} (Hervas et al., 2000; Rutter et al., 1995). Related to this, 5HT_{1A}R activation is associated with an acute anxiogenic response to SRI, examined with laboratory animals (Birkett et al., 2011; Greenwood et al., 2008). Indeed, SRI is known to have an anxiogenic effect in human patients, particularly during the early period of medical treatments (Bigos et al., 2008; Browning et al., 2007).

Functional activity of 5HT_{1A}Rs can be to some extent desensitized after long-term use of SRI (Blier, 2001; El Mansari et al., 2005). As a result, 5HT_{ext} elevation is slightly augmented, most likely to around 2-3 fold (Dawson et al., 2000) but never more than 5-fold (Popa et al., 2010). It has been hypothesized that the desensitized 5HT_{1A}Rs together with increased 5HT_{ext} but neither alone, are two required elements for antidepressant treatments (Sharp et al., 2011). If the hypothesis were correct, it suggests that a less than 5-fold increase in 5HT_{ext} in the cerebrospinal fluid is sufficient for therapeutic purposes.

In addition to 5HT_{1A}Rs, other 5HTR subtypes could also affect the profile of SRI, thereby affecting 5HT_{ext} elevation (Cremers et al., 2007; Jongsma et al., 2005). This suggests that in the brain there exist several other feedback loops that collectively influence the effect of systemic administration of SRI. In other words, the response to SRI would be stronger after eliminating the feedback inhibition. Consistently, the 5HT_{ext} response is much higher when the drug administration is locally applied in the brain (Adell et al., 1991a; Hervas et al., 2000; Tao et al., 2000). The maximum elevation of 5HT_{ext} by local application of SRI can be 5-fold but less than 10-fold compared to the baseline. Although 5HT_{ext} at this level appears to be higher than normal, there is no evidence in the literature suggesting that a 5 to 9-fold increase is associated with mental impairment such as serotonin syndrome.

It should be kept in mind that 5HT reuptake is one of the important pathways for 5HT metabolism. Drugs that have an effect on the reuptake would likely pose the risk of interrupting the integrity of 5HT metabolism, particularly after long-term use (Moret et al., 1992; Stenfors et al., 2001). It has been shown that chronic treatment with SRI could reduce the amount of intracellular 5HT in some brain regions (Bianchi et al., 2002). Whether the reduced 5HT content would ultimately affect the SRI-evoked increase in 5HT_{ext} or whether such chronic effects on intracellular 5HT are associated with the development of treatment resistance in patients is not clear.

MAOIs are a family of drugs that inhibit the activity of the MAO-A isozyme located at the outer membrane of mitochondria in the synapses of serotonergic axon terminals, causing 5HT accumulation in the cytoplasmic compartment (Evraud et al., 2002; Ferrer et al., 1994). Since the capacity of the cytoplasm to retain 5HT molecules is very limited while the synaptic vesicles are full, the only place for the extravesicular 5HT is to “spillover” into the extracellular space. The mechanisms for 5HT spill are not fully elucidated, most likely through the transmitter carriers that reversely transport extravesicular 5HT into the extracellular space (Gobbi et al., 1993; Silva et al., 2008). Thus, administration of MAOIs
would cause an increase in $5HT_{ext}$ proportional to that of intracellular content (Ferrer et al., 1994). Normally, a maximum increase following systemic injection is about 1 to 2-fold above baseline (Ferrer et al., 1994; Rollema et al., 2011). The effect of MAOIs is also determined by dietary ingredients, particularly of those containing the 5HT precursor such as tryptophan and 5HTP. It deserves separate mention that one of the major side effects in the clinical use of the old generation of MAOIs is hypertensive crisis, known as “cheese reaction” due to ingestion with tyramine-rich diets. The good news is that the new generation of MAOIs has fewer side effects relevant to diet [reviewed by (Wimbiscus et al., 2010)]. Clinically, while SRIIs are widely used as a first-line drug to treat depression, MAOIs are often recommended for treatment-resistant depression. Similar to SRIIs, the MAOI-evoked increase in $5HT_{ext}$ is also regulated by feedback mechanisms involving $5HT_{1A}$Rs (Lanteri et al., 2009). Hence, like SRIIs, MAOIs could produce relatively higher increases after the feedback inhibition mechanism is eliminated or desensitized, showing a maximum elevation of 5-10 fold above baseline (Tao et al., 1994).

5HTP is recommended as a supplemental treatment for depression and menopausal hot flush (Curcio et al., 2005; Shaw et al., 2002). In humans, the typical 5HTP dosage is 100-300 mg/day or 1-3 mg/kg [reviewed by (Turner et al., 2006)]. In animals, 5HTP alone has no measurable effect on $5HT_{ext}$ except at a dose of 40 mg/kg and higher (Gartside et al., 1992; Perry et al., 1993). This implies that newly synthesized 5HT molecules can be rapidly metabolized before being accumulated in the extravesicular compartment for spontaneous release. Specifically, $5HT_{ext}$ was increased by 2-fold in response to 75 mg/kg 5HTP (Nakatani et al., 2008) and by 4-fold in response to 100 mg/kg 5HTP (Gartside et al., 1992). In summary, it appears that 5HTP alone at the dose typically used in human patients has little contribution to the level of $5HT_{ext}$.

2.3 Dangerous elevations of $5HT_{ext}$: How much $5HT_{ext}$ in the CNS is too much?

There is no doubt that $5HT_{ext}$ is tightly regulated as a part of a homeostasis, most likely remaining at a low nanomolar concentration for maintaining normal brain function. Hypothetically, $5HT_{ext}$ in patients with major depression is too low to stimulate 5HTRs for an affective process (such as mood). 5HT-promoting drugs could lift mood by correcting $5HT_{ext}$ level. The amount of 5HT elevation is still at a small scale when drugs are used alone (monopharmacy).

However, $5HT_{ext}$ could be overcorrected, particularly with medication switching and polypharmacy. Despite decades of clinical research, no laboratory test is available to monitor brain $5HT_{ext}$ during a drug regimen in humans. It has been suggested that the change in brain $5HT_{ext}$ is in parallel with changes in peripheral 5HT or 5HIAA measured in blood and urine (Alvarez et al., 1999; Bianchi et al., 2002; Celada et al., 1993). Metabolically, peripheral 5HT is however independent of 5HT in the CNS; how changes in peripheral 5HT in response to drug treatment can infer changes in the brain is not yet established.

Although drug treatments would improve the mental well-being scale in terms of psychological evaluations, patients are at risk of having “excessive” $5HT_{ext}$ in the brain. Thus, it is important to determine a safe range of $5HT_{ext}$ concentrations for improvement in mood without causing excessive $5HT_{ext}$-induced side effects. It has been suggested by in vivo microdialysis studies that 5HT-promoting drugs usually produce a nanomolar (nM) level of
5HT_{ext} in the cerebrospinal fluid. However, in vitro studies demonstrate that a micromolar (μM) concentration is required to have postsynaptic effects on 5HTR-containing neurons (Cornelisse et al., 2007; Marinelli et al., 2004). This discrepancy in 5HT_{ext} levels possibly represents the difference in microenvironments between the cerebrospinal fluid and synapses in the extracellular space. Conceivably, most 5HT molecules released from synapses are rapidly taken back by transporters while a small portion is diffused away from the synapses. If this is the case, synaptic 5HT concentration must be much higher than that in the cerebrospinal fluid measured by microdialysis. In addition, 5HT_{ext} released from synapses is not evenly distributed in vivo across postsynaptic cell membranes. The amount of distribution depends on the distance from the release site. The concept of concentration differences in microenvironments is also supported by other studies. For instance, utilizing fast-scan cyclic voltammetry at a time resolution of 100 msec, it has been observed that 5HT_{ext} at the extrasynaptic site was rapidly (~5 s) increased from nM to μM in response to electrical stimulation (Bunin et al., 1998). In contrast, comparable stimulations could only induce a 1-2 fold increase in 5HT_{ext} in the cerebrospinal fluid determined by microdialysis at intervals of 20 min (McQuade et al., 1997). This suggests that the 5HT_{ext} concentration in the extrasynapse compartment is much higher than in the cerebrospinal fluid, supporting the view of microenvironmental variation. Note that such high concentration of 5HT_{ext} at synapses and/or extrasynaptic sites may not cause a neural disorder because: 1) the time duration of the effect is usually only a few milliseconds; 2) numbers and types of synaptic neurons involved in the action are highly localized; 3) the neurotransmitter can be rapidly removed by 5HT reuptake transporters. However, it could be problematic if there are prolonged and widespread effects on many 5HTR-containing neurons.

Except for MDMA, few 5HT-promoting drugs acting alone could elevate 5HT to high levels for a long period. This may occur mainly when two or more 5HT metabolic pathways are simultaneously disrupted during medication switching or polypharmacy, resulting in “excessive” 5HT_{ext} that exerts an adverse effect on mental health. For instance, Shioda et al. investigated the interaction between MAOIs and SSRIs for understanding changes in 5HT_{ext} relevant to serotonin syndrome (Shioda et al., 2004). In their investigation, male Wistar rats received co-injection of tranylcypromine (3.5 mg/kg), a nonselective MAOI, and fluoxetine (10 mg/kg), an SSRI. Hypothalamic 5HT_{ext} was determined by microdialysis while serotonin syndrome was estimated by measuring body-core temperature and neuromuscular activity. The environmental temperature was set at 23 ±1 °C. Under this condition, drug interaction caused an increase in 5HT_{ext} by 40-fold above the pre-drug level, lasting at least 6 hours. There were obvious signs of serotonin syndrome including hyperthermia, head shakes and tremor, suggesting that 5HT_{ext} at this level causes both physical and behavioral problems. Since each drug alone could only evoke a 2-3 fold increase, it appears that their combined effect is not simply additive, but synergistic. Other neurotransmissions, for instance, dopaminergic and glutamatergic systems that usually are not affected by single drug treatments are also elevated. This suggests that neural circuits consisting of several neuronal systems are involved in the syndrome, which is beyond the scope of this analysis and will not be discussed further here.

It is critical to determine the threshold level of 5HT_{ext} responsible for evoking serotonin syndrome. Baumann et al examined the harmful potential of MDMA by scoring behavior signs of serotonin syndrome (e.g., flat-body posture and forepaw treading) in correlation with elevated 5HT_{ext} in the frontal cortex and nucleus accumbens of male Sprague-Dawley
How Much Serotonin in the CNS is Too Much?

57 rats (Baumann et al., 2008a; Baumann et al., 2008b). In their behavioral and neurochemical studies, animals received a first injection of MDMA at the dose of 1 mg/kg followed by a second injection of 3 mg/kg 60 min later. The ambient temperature in which animals were examined was 22±2 °C. As a result, $5HT_{ext}$ was increased by 5- to 8-fold in response to 1 mg/kg and 18- to 33-fold following 3 mg/kg. While MDMA at 1 mg/kg had no effect on animal behavior, 3 mg/kg of MDMA were able to induce symptoms of the serotonin syndrome, suggesting that the $5HT_{ext}$ threshold to evoke the serotonin syndrome may be in a range between 9 to 18-fold.

Compared to other 5HT-promoting drugs, a single injection of MDMA at clinically relevant doses has a transient effect on 5HT, lasting only 15-30 min in terms of peak effect. To obtain a significant response, many investigators employ multiple injections to mimic the binge use of MDMA in humans. Theoretically, multiple injections could produce several 5HT peak responses which would complicate the elucidation of causal relationships between 5HT and behavioral effects. To simplify the analysis, 5HT precursors (e.g., 5HTP) in combination with MAOI (e.g., clorgyline) are more applicable for elucidating the 5HT threshold. Many studies have demonstrated that a single injection of 5HTP combined with clorgyline was sufficient to produce a dose-dependent increase in $5HT_{ext}$ in the brain, causing serotonin syndrome (Ma et al., 2008; Nisijima et al., 2004; Nisijima et al., 2000; Nisijima et al., 2001; Shioda et al., 2004). To obtain the threshold level of $5HT_{ext}$ we designed a 5HTP dosing regimen in clorgyline-pretreated rats. Male Sprague–Dawley rats were examined under controlled ambient temperature (22 ± 1°C) and humidity (70%) in test chambers (Ma et al., 2008; Zhang et al., 2009). Animals received 2 mg/kg clorgyline, 2 hours before injection of 5HTP at the dose range of 1 to 25 mg/kg. $5HT_{ext}$ was determined in the frontal cortex and hypothalamus while behavioral responses were recorded with a 4-level scale by scoring the severity of tremor, head shakes, forepaw treading, hindlimb abduction, myotonia and Straub tail.

Specifically, $5HT_{ext}$ was potentially elevated to as high as 100-fold above baseline following a single injection of 5HTP into clorgyline-pretreated rats, consistent with the results of previous studies (Shioda et al., 2004). In fact, this level of $5HT_{ext}$ is already well over the threshold for inducing a serotonin syndrome. Our data showed that a 55-fold increase in $5HT_{ext}$ caused the severe syndrome manifested by high hyperthermia and all other typical signs described in animals (Jacobs et al., 1975) or severe symptoms resembling those described in humans (Mills, 1995). An open question is whether such a high $5HT_{ext}$ level is really evoked in the human brain despite drug interactions.

Our studies further demonstrated that a 10-fold increase in $5HT_{ext}$ was sufficient to cause a mild syndrome, showing hypothermia, head shakes and myoclonus but no signs indicative of advanced or severe syndrome (e.g., tremor, forepaw treading or hindlimb abduction) (Ma et al., 2008; Zhang et al., 2009). This suggests that the brain is most likely intolerant of the double digit increase in $5HT_{ext}$ in terms of fold-change in the cerebrospinal fluid. There was no syndrome-related behavioral changes in response to a 5- to 9-fold increase although head shakes were still apparent, supporting the conclusion that a single digit increase is highly tolerable. The head shaking behavior disappeared when the increased $5HT_{ext}$ decreased to 5-fold and less, consistent with suggestion that a less than 5-fold increase in $5HT_{ext}$ in the brain is essentially safe. Clearly, more investigation into this important area of research is needed. It is crucial to relate changes in behavior to changes in $5HT_{ext}$ level, particularly after long-term interactions between 5HT-promoting drugs.
3. Involvement of 5HT receptors

There are at least 14 subtypes of 5HT receptors (5HTRs) in the brain (Green, 2006). One may wonder what the role is an individual subtype in the development of the serotonin syndrome. It should be kept in mind that 5HT is the natural agonist for these subtypes in the brain; and involvement of individual subtypes depends on not only the availability of the agonist but also the binding affinity to the agonist. It has been recognized for many years that the strength of 5HT affinity can be widely different. For instance, a μM concentration may be required for binding 50% of low affinity 5HT2A Rs whereas a nM concentration for high affinity 5HT1A Rs (Dalpiaz et al., 1995; Peroutka et al., 1981; Peroutka et al., 1983). Thus, the role of each subtype in the syndrome is complicated, and depends on multiple factors.

For better comparison between subtypes, pKd or pKi values are commonly used to indicate the strength or the selectivity of ligands to a given subtype. It is worthy pointing out that their values are not always reliable or consistent between tests due to variables in experimental conditions. Despite this, they provide trends for estimating affinity between receptor and ligand. It is well known that affinity values are strongly associated with functional activity of receptors in the brain (Clemett et al., 1999; Knight et al., 2004; Rossi et al., 2008). Although few studies are available to completely map the affinity between 5HT and its receptor subtypes under the same condition, a valuable reference is found from the database provided by the International Union of Basic and Clinical Pharmacology or IUPHAR (Table 1). Based on their database, the 14 subtypes can be ranked in the order of affinity strength from high (sub-nM; or 10^-9 M) to low activity (μM or 10^-6 M). Although so many subtypes are available in the brain, it appears that they are not functioning simultaneously. Their neurological function is selectively elicited by 5HT in a concentration-dependent manner. For instance, 5HT at the concentration of approximately 10^-9 M could competitively displace 50% of competitors at the 5HT1A R site, implying that a sub-nM concentration is able to activate 5HT1A Rs. In support of this, as demonstrated in vitro in dorsal raphe slices, the inward current indicative of 5HT1A R activity can be elicited by 5HT at concentration less than 1 nM with the EC50 at 30 nM (Penington et al., 1993), closely in line with results obtained by radioligand binding assays. By contrast, other subtypes such as 5HT2A Rs are unlikely to be affected by 5HT at such a low concentration. It should be noted that 5HT1A Rs are densely located on the somatodendritic sites of serotonergic neurons in the raphe (Li et al., 1997) and their high binding affinity to 5HT is physiologically important for their role in negative feedback regulation.

5HT1A Rs are also distributed on many types of postsynaptic neurons (Bert et al., 2006), particularly glutamatergic and GABAergic neurons in the cortices (de Almeida et al., 2008; Martin-Ruiz et al., 2001). It has often been shown that these postsynaptic 5HT1A Rs can be activated by 5HT at a relatively high concentration between 1-10 μM (Goodfellow et al., 2009; Schmitz et al., 1998), controlling the functional balance between glutamate and GABA transmissions.

Thus, since 5HText in response to most psychoactive drugs is normally in a nanomolar range (Gardier et al., 2003), these postsynaptic receptors are unlikely to be able to be activated. In the case of 5HText exceeding maximum tolerable limits, there is a global activation of postsynaptic 5HT1A Rs, causing fluctuation of GABA and glutamate, two functionally opposite neurotransmitters. It is likely that this fluctuation in the CNS is responsible for neuromuscular hyperactivity (Paterson et al., 2009), but verification of this hypothesis
related to the serotonin syndrome involving head weaving, tremor and forepaw treading awaits for further investigation.

| 5HT<sub>1A</sub>R       | 9.1 – 9.7 |
|-------------------------|-----------|
| 5HT<sub>7</sub>R        | 8.1 – 9.6 |
| 5HT<sub>1D</sub>R       | 8.0 – 9.0 |
| 5ht<sub>1</sub>eR       | 8.0 – 8.2 |
| 5HT<sub>2B</sub>R       | 7.9 – 8.4 |
| 5HT<sub>1F</sub>R       | 7.7 – 8.0 |
| 5HT<sub>1B</sub>R       | 7.4 – 9.0 |
| 5HT<sub>2C</sub>R       | 6.8 – 8.6 |
| 5HT<sub>6</sub>eR        | 6.8 – 7.5 |
| 5ht<sub>5a</sub>eR       | 6.7 – 6.9 |
| 5HT<sub>3A</sub>R       | 6.5 – 6.9 |
| 5HT<sub>2A</sub>R       | 6.0 – 8.4 |
| 5HT<sub>3A</sub>R<sub>B</sub> | 6.0    |
| 5HT<sub>4</sub>eR        | 5.9 – 7.0 |

Data from the database provided by the International Union of Basic and Clinical Pharmacology or IUPHAR (http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?familyId=1&objectId=1)

Table 1. 5HT binding affinity (pK<sub>i</sub>)

Based on 5HT<sub>ext</sub> concentration, we suggest that the 5HT subtypes can be hypothetically classified into 5 groups: sub-nM, nM, high nM, sub-μM and μM. As elucidated in Table 2, more and more subtypes in the brain are involved when the concentration is increased. It is likely that, as 5HT<sub>ext</sub> exceeds its upper tolerable level, lower affinity subtypes are activated along with higher affinity ones.

| 5HT<sub>ext</sub> levels | Sub-nM | nM      | High nM | Sub-μM | μM      |
|--------------------------|--------|---------|---------|--------|---------|
| **Affected receptors**   |        |         |         |        |         |
| 5HT<sub>1A</sub>R (presynaptic) | 5HT<sub>1A</sub>R (presynaptic) | 5HT<sub>1A</sub>R (pre-postsynaptic) | 5HT<sub>1A</sub>R (pre-postsynaptic) |
| 5HT<sub>7</sub>R         | 5HT<sub>7</sub>R |
| 5HT<sub>2B</sub>R        | 5HT<sub>2B</sub>R |
| 5ht<sub>1</sub>eR        | 5ht<sub>1</sub>eR |
| 5HT<sub>1D</sub>R        | 5HT<sub>1D</sub>R |
| 5HT<sub>6</sub>eR        | 5HT<sub>6</sub>eR |
| 5HT<sub>3A</sub>R        | 5HT<sub>3A</sub>R |
| 5HT<sub>3A</sub>R<sub>B</sub> | 5HT<sub>3A</sub>R<sub>B</sub> |

Table 2. Neurological relationship between subtype activation and increased 5HT<sub>ext</sub>. More and more subtypes are activated as 5HT<sub>ext</sub> levels are increased from sub-nM to μM
Using a radioligand receptor binding assay, studies have shown that 5HT_{2A}Rs have low affinity and are not easily bound to 5HT (Peroutka et al., 1981; Peroutka et al., 1983). The significance of this finding has not been recognized simply because the threshold level of 5HT_{ext} concentration in maintaining mental health is not fully appreciated. 5HT_{2A}Rs are mainly (but not exclusively) distributed on glutamatergic neurons in the cortices (de Almeida et al., 2007) and are critical for regulating the interconnection between the cortex and raphe. It has been widely documented in _in vitro_ studies that 5HT_{2A}Rs cannot be activated until the 5HT concentration reaches 20-50 \( \mu M \) (Aghajanian et al., 1997; Zhou et al., 1999), suggesting that their activation threshold is much higher than 5HT_{1A}Rs. Importantly, the answer to whether 5HT_{2A}Rs are involved in the syndrome is a life-or-death issue. This is mainly because 5HT_{2A}Rs are the major receptor strongly associated with hyperthermia and other autonomic hyperactivity (Mazzola-Pomietto et al., 1995; Zhang et al., 2011). Hyperthermia is believed to be the major cause for severe brain injury as demonstrated by MDMA studies (Malberg et al., 1998). Collectively, the serotonin syndrome resulting from activation of 5HT_{1A}Rs and 5HT_{2A}Rs is associated with excessive 5HT_{ext} up to a single to double-digit \( \mu M \) concentration at synapses. This suggests that 5HT_{ext} in the synapse has arisen by 1000 times while it usually remains at a low nanomolar level. The effect is likely to correspond to a double-digit fold increase in the cerebrospinal fluid measured by _in vivo_ microdialysis (Zhang et al., 2009).

Most recent data have revealed that the functional activity of some 5HTR subtypes can be altered by environmental factors (Krishnamoorthy et al., 2010; Nicholas et al., 2003; Zhang et al., 2011). For instance, Nicholas et al demonstrated that, compared to a normal experimental condition, 5HT_{1A}R activity was markedly reduced in animals examined in warm ambient temperatures. On the other hand, the responsivity of 5HT_{2A}Rs could be markedly enhanced in warmer environments (Zhang et al., 2011). Similarly, it has been found in an _in vitro_ binding kinetic assay that 5HT affinity to 5HT_{2A}Rs was strongly increased in a temperature-dependent manner (Dalpiaz et al., 1995). Taken together, 5HT_{ext} concentration required for activation of 5HTRs may vary. Indeed, it has been observed that serotonin syndrome evoked by MDMA and other 5HT-promoting drugs is severely augmented in hot and crowded conditions at raves and dance clubs (Parrott, 2002) but ameliorated in a cooling environment (Krishnamoorthy et al., 2010).

### 4. Summary

The aim of this review is to elucidate possible ranges of brain 5HT_{ext} in association with therapeutic benefit, tolerable side effects and the development of serotonin syndrome. 5HT_{ext} is derived from either spontaneous release or active stimulation, which initially presents at synapses and subsequently diffuses into the cerebrospinal fluid. In contrast to 5HT at synapses, 5HT_{ext} in the cerebrospinal fluid can be easily determined by microdialysis. Physiologically, a low nanomolar concentration (nM) is crucial for normal function of maintaining constant activation of postsynaptic 5HTRs. In the case of depression, 5HT_{ext} is at a lower level, resulting in reduced activity of 5HTRs that can affect mood and behaviors. An appropriate elevation of 5HT_{ext} promotes a positive mood and an energized sense of physical well-being. Therapeutically, 5HT_{ext} elevated by 5HT-promoting drugs such as SRIs or MAOIs up to 5-fold in the cerebrospinal fluid is sufficient to improve the mood.
Unfortunately, MDMA (“Ecstasy”) hijacks such positive aspects of the serotonergic effect, causing drug abuse. Although generally safe, 5HT-promoting drugs could evoke an increase in 5HT\textsubscript{ext} in the cerebrospinal fluid exceeding 10-fold. When it occurs, the 5HT\textsubscript{ext} level in the synapses most likely reaches a single to double-digit μM concentration, which would globally activate 5HT\textsubscript{1AR}s and/or 5HT\textsubscript{2AR}s on glutamatergic and GABAergic neurons. Such global activation involved in both glutamate and GABA transmission leads to neurological disorders, which are manifested as serotonin syndrome. Importantly, the actions of 5HT\textsubscript{ext} on 5HTR\textsubscript{s} are highly variable, and strongly depend on behavioral states as well as external environments. Thus, the severity of the syndrome can vary from mild, to moderate, to life-threatening (Krishnamoorthy et al., 2010; Parrott, 2002).

5. Acknowledgements

The authors are grateful to Professor Howard Prentice for editorial assistance to the final manuscript. This research was supported by USPHS DA029863.

6. References

Adell, A. & Artigas, F. (1991a). Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study. *Naunyn Schmiedebers Arch Pharmacol*, 343, 237-44.

Adell, A., Carceller, A. & Artigas, F. (1991b). Regional distribution of extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the brain of freely moving rats. *J Neurochem*, 56, 709-12.

Aghajanian, G.K. & Marek, G.J. (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. *Neuropharmacology*, 36, 589-99.

Alvarez, J.C., Gluck, N., Arnulf, I., Quintin, P., Leboyer, M., Pecquery, R., Launay, J.M., Perez-Diaz, F. & Spreux-Varoquaux, O. (1999). Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. *Clin Pharmacol Ther*, 66, 617-24.

Baumann, M.H., Clark, R.D., Franken, F.H., Rutter, J.J. & Rothman, R.B. (2008a). Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. *Neuroscience*, 152, 773-84.

Baumann, M.H., Clark, R.D. & Rothman, R.B. (2008b). Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. *Pharmacol Biochem Behav*, 90, 208-17.

Baumann, M.H., Wang, X. & Rothman, R.B. (2007). 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. *Psychopharmacology (Berl)*, 189, 407-424.

Becquet, D., Faudon, M. & Hery, F. (1990). The role of serotonin release and autoreceptors in the dorsalis raphe nucleus in the control of serotonin release in the cat caudate nucleus. *Neuroscience*, 39, 639-47.
Bert, B., Fink, H., Hortnagl, H., Veh, R.W., Davies, B., Theuring, F. & Kusserow, H. (2006). Mice over-expressing the 5-HT_{1A} receptor in cortex and dentate gyrus display exaggerated locomotor and hypothermic response to 8-OH-DPAT. *Behav Brain Res*, 167, 328-41.

Beyer, C.E. & Cremers, T.I. (2008). Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? *Eur J Pharmacol*, 580, 350-4.

Bhide, N.S., Lipton, J.W., Cunningham, J.I., Yamamoto, B.K. & Gudelsky, G.A. (2009). Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain. *Brain Res*, 1286, 32-41.

Bianchi, M., Moser, C., Lazzarini, C., Vecchiato, E. & Crespi, F. (2002). Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. *Exp Brain Res*, 143, 191-7.

Bigos, K.L., Pollock, B.G., Aizenstein, H.J., Fisher, P.M., Bies, R.R. & Hariri, A.R. (2008). Acute 5-HT reuptake blockade potentiates human amygdala reactivity. *Neuropsychopharmacology*, 33, 3221-5.

Birkett, M.A., Shinday, N.M., Kessler, E.J., Meyer, J.S., Ritchie, S. & Rowlett, J.K. (2011). Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice. *Pharmacol Biochem Behav*, 98, 544-51.

Blier, P. (2001). Pharmacology of rapid-onset antidepressant treatment strategies. *J Clin Psychiatry*, 62 Suppl 15, 12-7.

Boyer, E.W. & Shannon, M. (2005). The serotonin syndrome. *N Engl J Med*, 352, 1112-20.

Browning, M., Reid, C., Cowen, P.J., Goodwin, G.M. & Harmer, C.J. (2007). A single dose of citalopram increases fear recognition in healthy subjects. *J Psychopharmacol*, 21, 684-90.

Bruns, D. & Jahn, R. (1995). Real-time measurement of transmitter release from single synaptic vesicles. *Nature*, 377, 62-5.

Bruns, D., Riedel, D., Klingauf, J. & Jahn, R. (2000). Quantal release of serotonin. *Neuron*, 28, 205-20.

Bunin, M.A. & Wightman, R.M. (1998). Quantitative evaluation of 5-hydroxytryptamine (serotonin) neuronal release and uptake: an investigation of extrasynaptic transmission. *J Neurosci*, 18, 4854-60.

Calcagno, E., Canetta, A., Guzzetti, S., Cervo, L. & Invernizzi, R.W. (2007). Strain differences in basal and post-citalopram extracellular 5-HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase-2 activity. *J Neurochem*, 103, 1111-20.

Celada, P. & Artigas, F. (1993). Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues. *J Neurochem*, 61, 2191-8.

Clemett, D.A., Kendall, D.A., Cockett, M.I., Marsden, C.A. & Fone, K.C. (1999). Pindolol-insensitive [3H]-5-hydroxytryptamine binding in the rat hypothalamus; identity with 5-hydroxytryptamine7 receptors. *Br J Pharmacol*, 127, 236-42.
Cornelisse, L.N., Van der Harst, J.E., Lodder, J.C., Baarendse, P.J., Timmerman, A.J., Mansvelder, H.D., Spruijt, B.M. & Brussaard, A.B. (2007). Reduced 5-HT$_{1A}$- and GABA$_B$ receptor function in dorsal raphe neurons upon chronic fluoxetine treatment of socially stressed rats. *J Neurophysiol*, 98, 196-204.

Cremers, T.I., Rea, K., Bosker, F.J., Wikstrom, H.V., Hogg, S., Mork, A. & Westerink, B.H. (2007). Augmentation of SSRI effects on serotonin by 5-HT$_{2C}$ antagonists: mechanistic studies. *Neuropsychopharmacology*, 32, 1550-7.

Curcio, J.J., Kim, L.S., Wollner, D. & Pockaj, B.A. (2005). The potential of 5-hydroxytryptophan for hot flash reduction: a hypothesis. *Altern Med Rev*, 10, 216-21.

Dalpiaz, A., Gessi, S., Borea, P.A. & Gilli, G. (1995). Binding thermodynamics of serotonin to rat-brain 5-HT$_{1A}$, 5-HT$_{2A}$ and 5-HT$_{3}$ receptors. *Life Sci*, 57, PL141-6.

David, D.J., Bourin, M., Jego, G., Przybylski, C., Jolliet, P. & Gardier, A.M. (2003). Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. *Br J Pharmacol*, 140, 1128-36.

Dawson, L.A., Nguyen, H.Q., Smith, D.I. & Scheckter, L.E. (2000). Effects of chronic fluoxetine treatment in the presence and absence of (±)pindolol: a microdialysis study. *Br J Pharmacol*, 130, 797-804.

de Almeida, J. & Mengod, G. (2007). Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT$_{2A}$ receptors in human and monkey prefrontal cortex. *J Neurochem*, 103, 475-86.

de Almeida, J. & Mengod, G. (2008). Serotonin 1A receptors in human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic interneuron subpopulation: implications for schizophrenia and its treatment. *J Neurochem*, 107, 488-96.

El Mansari, M. & Blier, P. (2005). Responsiveness of 5-HT$_{1A}$ and 5-HT$_{2}$ receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. *J Psychiatry Neurosci*, 30, 268-74.

Evrard, A., Malagie, I., Laporte, A.M., Boni, C., Hanoun, N., Trillat, A.C., Seif, I., De Maeyer, E., Gardier, A., Hamon, M. & Adrien, J. (2002). Altered regulation of the 5-HT system in the brain of MAO-A knock-out mice. *Eur J Neurosci*, 15, 841-51.

Ferrer, A. & Artigas, F. (1994). Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain. *Eur J Pharmacol*, 263, 227-34.

Gardier, A.M., David, D.J., Jego, G., Przybylski, C., Jacquot, C., Durier, S., Gruwez, B., Douvier, E., Beuverie, P., Poisson, N., Hen, R. & Bourin, M. (2003). Effects of chronic paroxetine treatment on dialysate serotonin in 5-HT$_{1B}$ receptor knockout mice. *J Neurochem*, 86, 13-24.

Gartside, S.E., Cowen, P.J. & Sharp, T. (1992). Effect of 5-hydroxy-L-tryptophan on the release of 5-HT in rat hypothalamus in vivo as measured by microdialysis. *Neuropharmacology*, 31, 9-14.

Gobbi, M., Frittoli, E., Uslenghi, A. & Mennini, T. (1993). Evidence of an exocytotic-like release of $[^{3}H]5$-hydroxytryptamine induced by d-fenfluramine in rat hippocampal synaptosomes. *Eur J Pharmacol*, 238, 9-17.
Goodfellow, N.M., Benekareddy, M., Vaidya, V.A. & Lambe, E.K. (2009). Layer II/III of the prefrontal cortex: Inhibition by the serotonin 5-HT1A receptor in development and stress. J Neurosci, 29, 10094-103.

Grahame-Smith, D.G. & Green, A.R. (1974). The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol, 52, 19-26.

Green, R.A. (2006). Neuropharmacology of 5-hydroxytryptamine. Br J Pharmacol, 147 Suppl 1, S145-52.

Greenwood, B.N., Strong, P.V., Brooks, L. & Fleshner, M. (2008). Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise. Psychopharmacology (Berl), 199, 209-22.

Hervas, I., Queiroz, C.M., Adell, A. & Artigas, F. (2000). Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br J Pharmacol, 130, 160-6.

Jacobs, B.L. & Klemfuss, H. (1975). Brain stem and spinal cord mediation of a serotonergic behavioral syndrome. Brain Res, 100, 450-7.

Jongsma, M.E., Bosker, F.J., Cremers, T.I., Westerink, B.H. & den Boer, J.A. (2005). The effect of chronic selective serotonin reuptake inhibitor treatment on serotonin 1B receptor sensitivity and HPA axis activity. Prog Neuropsychopharmacol Biol Psychiatry, 29, 738-44.

Karunatilake, H. & Buckley, N.A. (2006). Serotonin syndrome induced by fluvoxamine and oxycodone. Ann Pharmacother, 40, 155-7.

Kim, D.K., Tolliver, T.J., Huang, S.J., Martin, B.J., Andrews, A.M., Wichems, C., Holmes, A., Lesch, K.P. & Murphy, D.L. (2005). Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology, 49, 798-810.

Knight, A.R., Misra, A., Quirk, K., Benwell, K., Revell, D., Kennett, G. & Bickerdike, M. (2004). Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol, 370, 114-23.

Krishnamoorthy, S., Ma, Z., Zhang, G., Wei, J., Auerbach, S.B. & Tao, R. (2010). Involvement of 5-HT2A Receptors in the Serotonin (5-HT) Syndrome caused by Excessive 5-HT Efflux in Rat Brain. Basic Clin Pharmacol Toxicol, 107, 830-41.

Lanteri, C., Hernandez Vallejo, S.J., Salomon, L., Doucet, E.L., Godeheu, G., Torrens, Y., Houades, V. & Tassin, J.P. (2009). Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization. J Neurosci, 29, 987-97.

Li, Q., Battaglia, G. & Van de Kar, L.D. (1997). Autoradiographic evidence for differential G-protein coupling of 5-HT1A receptors in rat brain: lack of effect of repeated injections of fluoxetine. Brain Res, 769, 141-51.

Ma, Z., Zhang, G., Jenney, C., Krishnamoorthy, S. & Tao, R. (2008). Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats. Eur J Pharmacol, 588, 198-206.
Malberg, J.E. & Seiden, L.S. (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci, 18, 5086-94.

Marinelli, S., Schnell, S.A., Hack, S.P., Christie, M.J., Wessendorf, M.W. & Vaughan, C.W. (2004). Serotonergic and nonserotonergic dorsal raphe neurons are pharmacologically and electrophysiologically heterogeneous. J Neurophysiol, 92, 3532-7.

Martin-Ruiz, R., Puig, M.V., Celada, P., Shapiro, D.A., Roth, B.L., Mengod, G. & Artigas, F. (2001). Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci, 21, 9856-66.

Mathews, T.A., Fedele, D.E., Coppelli, F.M., Avila, A.M., Murphy, D.L. & Andrews, A.M. (2004). Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods, 140, 169-81.

Mazzola-Pomietto, P., Aulakh, C.S., Wozniak, K.M., Hill, J.L. & Murphy, D.L. (1995). Evidence that 1-(2,5-dimethoxy-4-iodo phenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology (Berl), 117, 193-9.

McQuade, R. & Sharp, T. (1997). Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J Neurochem, 69, 791-6.

Mills, K.C. (1995). Serotonin syndrome. Am Fam Physician, 52, 1475-82.

Moret, C. & Briley, M. (1992). Effect of antidepressant drugs on monoamine synthesis in brain in vivo. Neuropharmacology, 31, 679-84.

Nakatani, Y., Sato-Suzuki, I., Tsujino, N., Nakasato, A., Seki, Y., Fumoto, M. & Arita, H. (2008). Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci, 27, 2466-72.

Nicholas, A.C. & Seiden, L.S. (2003). Ambient temperature influences core body temperature response in rat lines bred for differences in sensitivity to 8-hydroxydipropylaminotetralin. J Pharmacol Exp Ther, 305, 368-74.

Nisijima, K., Shioda, K., Yoshino, T., Takano, K. & Kato, S. (2004). Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry, 37, 57-62.

Nisijima, K., Yoshino, T. & Ishiguro, T. (2000). Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology (Berl), 150, 9-14.

Nisijima, K., Yoshino, T., Yui, K. & Katoh, S. (2001). Potent serotonin (5-HT2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res, 890, 23-31.

Parker, G. & Brotchie, H. (2011). Mood effects of the amino acids tryptophan and tyrosine: 'Food for Thought' III. Acta Psychiatr Scand.

Parrott, A.C. (2002). Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav, 71, 837-44.
Parsons, B., Roxas, A., Jr., Huang, Y.Y., Dwork, A. & Stanley, M. (1992). Regional studies of serotonin and dopamine metabolism and quantification of serotonin uptake sites in human cerebral cortex. *J Neural Transm Gen Sect*, 87, 63-75.

Paruchuri, P., Godkar, D., Anandacoomarswamy, D., Sheth, K. & Niranjan, S. (2006). Rare case of serotonin syndrome with therapeutic doses of paroxetine. *Am J Ther*, 13, 550-2.

Paterson, N.E., Malekiani, S.A., Foreman, M.M., Olivier, B. & Hanania, T. (2009). Pharmacological characterization of harmaline-induced tremor activity in mice. *Eur J Pharmacol*, 616, 73-80.

Penington, N.J., Kelly, J.S. & Fox, A.P. (1993). Whole-cell recordings of inwardly rectifying K+ currents activated by 5-HT1A receptors on dorsal raphe neurones of the adult rat. *J Physiol*, 469, 387-405.

Peroutka, S.J., Lebovitz, R.M. & Snyder, S.H. (1981). Two distinct central serotonin receptors with different physiological functions. *Science*, 212, 827-9.

Peroutka, S.J. & Snyder, S.H. (1983). Multiple serotonin receptors and their physiological significance. *Fed Proc*, 42, 213-7.

Perry, K.W. & Fuller, R.W. (1993). Extracellular 5-hydroxytryptamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-hydroxytryptophan. *J Pharm Pharmacol*, 45, 759-61.

Popa, D., Cerdan, J., Reperant, C., Guiard, B.P., Guilloux, J.P., David, D.J. & Gardier, A.M. (2010). A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. *Eur J Pharmacol*, 628, 83-90.

Pothakos, K., Robinson, J.K., Gravanis, I., Marsteller, D.A., Dewey, S.L. & Tsirka, S.E. (2010). Decreased serotonin levels associated with behavioral disinhibition in tissue plasminogen activator deficient (tPA-/-) mice. *Brain Res*, 1326, 135-42.

Rollema, H., Wilson, G.G., Lee, T.C., Folgering, J.H. & Flik, G. (2011). Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex. *Neurochem Int*, 58, 78-84.

Rossi, D.V., Burke, T.F., McCasland, M. & Hensler, J.G. (2008). Serotonin-1A receptor function in the dorsal raphe nucleus following chronic administration of the selective serotonin reuptake inhibitor sertraline. *J Neurochem*, 105, 1091-9.

Rutter, J.J. & Auerbach, S.B. (1993). Acute uptake inhibition increases extracellular serotonin in the rat forebrain. *J Pharmacol Exp Ther*, 265, 1319-24.

Rutter, J.J., Gundlah, C. & Auerbach, S.B. (1995). Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. *Synapse*, 20, 225-33.

Schaefer, T.L., Skelton, M.R., Herring, N.R., Gudelsky, G.A., Vorhees, C.V. & Williams, M.T. (2008). Short- and long-term effects of (+)-methamphetamine and (+)-3,4-methylenedioxyamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment. *J Neurochem*, 104, 1674-85.

Schmitz, D., Gloveli, T., Empson, R.M., Draguhn, A. & Heinemann, U. (1998). Serotonin reduces synaptic excitation in the superficial medial entorhinal cortex of the rat via a presynaptic mechanism. *J Physiol*, 508 (Pt 1), 119-29.
Seidl, R., Kaehler, S.T., Prast, H., Singewald, N., Cairns, N., Gratzer, M. & Lubec, G. (1999). Serotonin (5-HT) in brains of adult patients with Down syndrome. *J Neural Transm Suppl*, 57, 221-32.

Sharp, T., Boothman, L., Raley, J. & Queree, P. (2007). Important messages in the ‘post’: recent discoveries in 5-HT neurone feedback control. *Trends Pharmacol Sci*, 28, 629-36.

Sharp, T. & Cowen, P.J. (2011). 5-HT and depression: is the glass half-full? *Curr Opin Pharmacol*, 11, 45-51.

Shaw, K., Turner, J. & Del Mar, C. (2002). Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. *Aust N Z J Psychiatry*, 36, 488-91.

Shioda, K., Nisijima, K., Yoshino, T. & Kato, S. (2004). Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. *Prog Neuropsychopharmacol Biol Psychiatry*, 28, 633-40.

Silva, J.H., Gomez, M.V., Guatimosim, C. & Gomez, R.S. (2008). Halothane induces vesicular and carrier-mediated release of [3H]serotonin from rat brain cortical slices. *Neurochem Int*, 52, 1240-6.

Spanos, L.J. & Yamamoto, B.K. (1989). Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat. *Pharmacol Biochem Behav*, 32, 835-40.

Stenfors, C., Yu, H. & Ross, S.B. (2001). Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram. *Naunyn Schmiedebergs Arch Pharmacol*, 363, 222-32.

Sternbach, H. (1991). The serotonin syndrome. *Am J Psychiatry*, 148, 705-13.

Tao, R. & Auerbach, S.B. (1994). Increased extracellular serotonin in rat brain after systemic or intraraphe administration of morphine. *J Neurochem*, 63, 517-24.

Tao, R., Ma, Z. & Auerbach, S.B. (2000). Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin. *J Pharmacol Exp Ther*, 294, 571-9.

Turner, E.H., Loftis, J.M. & Blackwell, A.D. (2006). Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. *Pharmacol Ther*, 109, 325-38.

Wimbiscus, M., Kostenko, O. & Malone, D. (2010). MAO inhibitors: risks, benefits, and lore. *Cleve Clin J Med*, 77, 859-82.

Wolf, W.A. & Kuhn, D.M. (1986). Uptake and release of tryptophan and serotonin: an HPLC method to study the flux of endogenous 5-hydroxyindoles through synaptosomes. *J Neurochem*, 46, 61-7.

Zhang, G., Krishnamoorthy, S., Ma, Z., Vukovich, N.P., Huang, X. & Tao, R. (2009). Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome. *Eur J Pharmacol*, 615, 66-75.

Zhang, G. & Tao, R. (2011). Enhanced responsivity of 5-HT2A receptors at warm ambient temperatures is responsible for the augmentation of the 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia. *Neurosci Lett*, 490, 68-71.
Zhou, F.M. & Hablitz, J.J. (1999). Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. *J Neurophysiol*, 82, 2989-99.
In this book we have experts writing on various neuroscience topics ranging from mental illness, syndromes, compulsive disorders, brain cancer and advances in therapies and imaging techniques. Although diverse, the topics provide an overview of an array of diseases and their underlying causes, as well as advances in the treatment of these ailments. This book includes three chapters dedicated to neurodegenerative diseases, undoubtedly a group of diseases of huge socio-economic importance due to the number of people currently suffering from this type of disease but also the prediction of a huge increase in the number of people becoming afflicted. The book also includes a chapter on the molecular and cellular aspects of brain cancer, a disease which is still amongst the least treatable of cancers.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Rui Tao and Zhiyuan Ma (2012). How Much Serotonin in the CNS is Too Much?, When Things Go Wrong - Diseases and Disorders of the Human Brain, Dr. Theo Mantamadiotis (Ed.), ISBN: 978-953-51-0111-6, InTech, Available from: http://www.intechopen.com/books/when-things-go-wrong-diseases-and-disorders-of-the-human-brain/how-much-serotonin-in-the-cns-is-too-much-